Overview

ProNeura offers continuous drug delivery and consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6 to 12 months.

Overview

Making Products with ProNeura

The drug substance that is part of the ProNeura implant is released slowly into the patient's body at continuous levels, through the process of dissolution. This results in a stable level of medication in the blood, similar to intravenous administration. Such long-term, linear release characteristics are generally desirable, as this avoids peak-and-trough level dosing that poses problems in the treatment of several chronic diseases.

Making Products with ProNeura

How ProNeura is Made

In the case of Probuphine®, the ProNeura implant contains 80 mg of buprenorphine HCl, uniformly distributed throughout the EVA matrix.

Eva Polymer
Eva Polymer
buprenorphine
Buprenorphine
Blended & Extruded
probuphine
Probuphine®

Competitive Advantage of ProNeura

By providing continuous, stable blood levels of medication, the ProNeura subdermal implant has the potential to offer several significant benefits to patients compared with other routes of administration. In addition to potential safety, efficacy and tolerability advantages resulting from long-term, non-fluctuating drug exposure, ProNeura would be implanted in a short, outpatient procedure once every three months to a year, making it more convenient for patients and enhancing compliance.

Product Pipeline

Probuphine®

for the treatment of Opioid Addiction

Market completed
Market completed
Market completed
Market completed
Market in progress
Preclinical Phase 1 Phase 2 Phase 3 Market
More About Probuphine®

Product Pipeline

Ropinirole Implant

for the treatment of Parkinson's Disease

Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market
More About Ropinirole Implant

Product Pipeline

T3 Implant

for the treatment of Hypothyroidism

Preclinical in progress
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical not started
Preclinical Phase 1 Phase 2 Phase 3 Market
More About T3 Implant